Research Analysts Set Expectations for ENLV Q1 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.02) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($0.09) EPS.

Other research analysts have also issued reports about the company. Wall Street Zen lowered Enlivex Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $16.50.

Enlivex Therapeutics Stock Performance

NASDAQ ENLV opened at $0.83 on Wednesday. Enlivex Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.10. The stock has a market capitalization of $197.83 million, a PE ratio of -1.52 and a beta of 1.68. The stock has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $1.02.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in Enlivex Therapeutics by 99.4% in the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after purchasing an additional 156,336 shares in the last quarter. HRT Financial LP raised its position in Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares in the last quarter. Jane Street Group LLC raised its position in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares in the last quarter. Susquehanna International Group LLP acquired a new position in Enlivex Therapeutics during the third quarter worth $57,000. Finally, Invesco Ltd. acquired a new position in Enlivex Therapeutics during the fourth quarter worth $43,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.